- 2026-12-06
-
Surufatinib combined with toripalimab in patients with recurrent ovarian clear cell carcinoma: updated results from a prospective single center, single-arm phase II clinical trial
07:46-07:53
Room 502
Mini Oral
Speaker

Wenbin Shen
Surufatinib combined with toripalimab in patients with recurrent ovarian clear cell carcinoma: updated results from a prospective single center, single-arm phase II clinical trial
07:46-07:53
Room 502
Mini Oral
Speaker